Nephros, Inc. (NEPH)
USD 1.48
(-3.9%)
USD 1.48
(-3.9%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.59 Million USD | 63.25% |
| 2022 | -4.33 Million USD | 0.0% |
| 2021 | -4.33 Million USD | 3.75% |
| 2020 | -4.5 Million USD | -36.03% |
| 2019 | -3.31 Million USD | -9.78% |
| 2018 | -3.01 Million USD | -35.49% |
| 2017 | -2.22 Million USD | 22.41% |
| 2016 | -2.86 Million USD | 16.14% |
| 2015 | -3.42 Million USD | -28.18% |
| 2014 | -2.66 Million USD | 19.54% |
| 2013 | -3.31 Million USD | 0.48% |
| 2012 | -3.33 Million USD | -44.29% |
| 2011 | -2.31 Million USD | -22.29% |
| 2010 | -1.88 Million USD | 21.49% |
| 2009 | -2.4 Million USD | 64.18% |
| 2008 | -6.71 Million USD | 10.19% |
| 2007 | -7.47 Million USD | 6.88% |
| 2006 | -8.03 Million USD | -26.99% |
| 2005 | -6.32 Million USD | 17.29% |
| 2004 | -7.64 Million USD | -53.1% |
| 2003 | -4.99 Million USD | -143.04% |
| 2002 | -2.05 Million USD | -88.41% |
| 2001 | -1.09 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -200 Thousand USD | 69.18% |
| 2024 Q2 | -317 Thousand USD | -58.5% |
| 2023 Q1 | -306 Thousand USD | 55.84% |
| 2023 FY | -1.59 Million USD | 63.25% |
| 2023 Q4 | -649 Thousand USD | -219.7% |
| 2023 Q3 | -203 Thousand USD | 53.33% |
| 2023 Q2 | -435 Thousand USD | -42.16% |
| 2022 Q2 | -1.2 Million USD | 38.35% |
| 2022 Q1 | -1.95 Million USD | -88.15% |
| 2022 FY | -4.33 Million USD | 0.0% |
| 2022 Q4 | -693 Thousand USD | 45.9% |
| 2022 Q3 | -1.28 Million USD | -6.4% |
| 2021 Q1 | -1.01 Million USD | -41.59% |
| 2021 Q2 | -1.11 Million USD | -9.72% |
| 2021 Q3 | -1.16 Million USD | -4.03% |
| 2021 Q4 | -1.03 Million USD | 10.67% |
| 2021 FY | -4.33 Million USD | 3.75% |
| 2020 Q3 | -932 Thousand USD | 41.68% |
| 2020 Q2 | -1.59 Million USD | -55.75% |
| 2020 FY | -4.5 Million USD | -36.03% |
| 2020 Q4 | -719 Thousand USD | 22.85% |
| 2020 Q1 | -1.02 Million USD | -252.58% |
| 2019 Q4 | -291 Thousand USD | 58.13% |
| 2019 Q3 | -695 Thousand USD | 19.93% |
| 2019 FY | -3.31 Million USD | -9.78% |
| 2019 Q2 | -868 Thousand USD | 33.28% |
| 2019 Q1 | -1.3 Million USD | -78.46% |
| 2018 Q1 | -1.12 Million USD | -178.66% |
| 2018 FY | -3.01 Million USD | -35.49% |
| 2018 Q4 | -729 Thousand USD | -42.66% |
| 2018 Q3 | -511 Thousand USD | 21.75% |
| 2018 Q2 | -653 Thousand USD | 41.85% |
| 2017 Q1 | -605 Thousand USD | 0.66% |
| 2017 FY | -2.22 Million USD | 22.41% |
| 2017 Q4 | -403 Thousand USD | 22.2% |
| 2017 Q3 | -518 Thousand USD | 26.0% |
| 2017 Q2 | -700 Thousand USD | -15.7% |
| 2016 Q3 | -637 Thousand USD | 22.03% |
| 2016 Q1 | -806 Thousand USD | 13.89% |
| 2016 Q2 | -817 Thousand USD | -1.36% |
| 2016 Q4 | -609 Thousand USD | 4.4% |
| 2016 FY | -2.86 Million USD | 16.14% |
| 2015 Q3 | -1.08 Million USD | -83.0% |
| 2015 Q2 | -594 Thousand USD | 26.3% |
| 2015 FY | -3.42 Million USD | -28.18% |
| 2015 Q4 | -936 Thousand USD | 13.89% |
| 2015 Q1 | -806 Thousand USD | -2.03% |
| 2014 Q4 | -790 Thousand USD | -16.01% |
| 2014 FY | -2.66 Million USD | 19.54% |
| 2014 Q3 | -681 Thousand USD | -7.08% |
| 2014 Q2 | -636 Thousand USD | -13.17% |
| 2014 Q1 | -562 Thousand USD | 35.25% |
| 2013 FY | -3.31 Million USD | 0.48% |
| 2013 Q3 | -608 Thousand USD | 3.18% |
| 2013 Q2 | -628 Thousand USD | 48.18% |
| 2013 Q4 | -868 Thousand USD | -42.76% |
| 2013 Q1 | -1.21 Million USD | -8.99% |
| 2012 Q1 | -556 Thousand USD | 13.26% |
| 2012 FY | -3.33 Million USD | -44.29% |
| 2012 Q3 | -853 Thousand USD | -5.05% |
| 2012 Q4 | -1.11 Million USD | -30.36% |
| 2012 Q2 | -812 Thousand USD | -46.04% |
| 2011 Q1 | -646 Thousand USD | -6.95% |
| 2011 Q2 | -598 Thousand USD | 7.43% |
| 2011 Q4 | -641 Thousand USD | -50.82% |
| 2011 Q3 | -425 Thousand USD | 28.93% |
| 2011 FY | -2.31 Million USD | -22.29% |
| 2010 Q1 | -527 Thousand USD | 0.38% |
| 2010 Q3 | -393 Thousand USD | -7.38% |
| 2010 Q4 | -604 Thousand USD | -53.69% |
| 2010 FY | -1.88 Million USD | 21.49% |
| 2010 Q2 | -366 Thousand USD | 30.55% |
| 2009 Q2 | -594 Thousand USD | 19.73% |
| 2009 FY | -2.4 Million USD | 64.18% |
| 2009 Q4 | -529 Thousand USD | 2.58% |
| 2009 Q1 | -740 Thousand USD | 21.19% |
| 2009 Q3 | -543 Thousand USD | 8.59% |
| 2008 Q4 | -939 Thousand USD | 31.86% |
| 2008 FY | -6.71 Million USD | 10.19% |
| 2008 Q1 | -1.77 Million USD | 31.72% |
| 2008 Q2 | -2.62 Million USD | -47.75% |
| 2008 Q3 | -1.37 Million USD | 47.48% |
| 2007 Q2 | -1.54 Million USD | -2.04% |
| 2007 Q4 | -2.6 Million USD | -43.62% |
| 2007 Q3 | -1.81 Million USD | -16.91% |
| 2007 FY | -7.47 Million USD | 6.88% |
| 2007 Q1 | -1.51 Million USD | 31.86% |
| 2006 FY | -8.03 Million USD | -26.99% |
| 2006 Q3 | -1.9 Million USD | 13.09% |
| 2006 Q4 | -2.22 Million USD | -17.05% |
| 2006 Q1 | -2.08 Million USD | -5.76% |
| 2006 Q2 | -2.18 Million USD | -4.97% |
| 2005 Q3 | -1.8 Million USD | 13.68% |
| 2005 Q4 | -1.97 Million USD | -9.08% |
| 2005 Q1 | -448.89 Thousand USD | 78.24% |
| 2005 Q2 | -2.09 Million USD | -366.66% |
| 2005 FY | -6.32 Million USD | 17.29% |
| 2004 Q4 | -2.06 Million USD | -9.46% |
| 2004 Q2 | -1.84 Million USD | 0.0% |
| 2004 FY | -7.64 Million USD | -53.1% |
| 2004 Q3 | -1.88 Million USD | -1.86% |
| 2003 FY | -4.99 Million USD | -143.04% |
| 2002 FY | -2.05 Million USD | -88.41% |
| 2001 FY | -1.09 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -57.66 Million USD | 97.238% |
| AngioDynamics, Inc. | -97.71 Million USD | 98.37% |
| AtriCure, Inc. | -26.68 Million USD | 94.03% |
| Avinger, Inc. | -16.63 Million USD | 90.424% |
| Azenta, Inc. | -73.12 Million USD | 97.822% |
| BioLife Solutions, Inc. | -70.82 Million USD | 97.751% |
| The Cooper Companies, Inc. | 533.1 Million USD | 100.299% |
| Daxor Corporation | -177.07 Thousand USD | -799.619% |
| Ekso Bionics Holdings, Inc. | -15.11 Million USD | 89.459% |
| Femasys Inc. | -14.5 Million USD | 89.02% |
| GlucoTrack, Inc. | -7.1 Million USD | 77.576% |
| Harvard Bioscience, Inc. | 1.89 Million USD | 184.108% |
| Hologic, Inc. | 882.6 Million USD | 100.18% |
| ICU Medical, Inc. | 22.82 Million USD | 106.979% |
| Intuitive Surgical, Inc. | 1.76 Billion USD | 100.09% |
| KORU Medical Systems, Inc. | -10.26 Million USD | 84.489% |
| LeMaitre Vascular, Inc. | 37.08 Million USD | 104.296% |
| Innovative Eyewear, Inc. | -6.9 Million USD | 76.915% |
| Innovative Eyewear, Inc. | -6.9 Million USD | 76.915% |
| Masimo Corporation | 136.5 Million USD | 101.167% |
| Microbot Medical Inc. | -9.85 Million USD | 83.836% |
| Meihua International Medical Technologies Co., Ltd. | 14.67 Million USD | 110.855% |
| Merit Medical Systems, Inc. | 123.94 Million USD | 101.285% |
| NovoCure Limited | -232.87 Million USD | 99.316% |
| NEXGEL, Inc. | -3.47 Million USD | 54.185% |
| NEXGEL, Inc. | -3.47 Million USD | 54.185% |
| Singular Genomics Systems, Inc. | -102.8 Million USD | 98.45% |
| OraSure Technologies, Inc. | 54.07 Million USD | 102.946% |
| Pro-Dex, Inc. | 7.17 Million USD | 122.208% |
| Pulse Biosciences, Inc. | -43.57 Million USD | 96.344% |
| Predictive Oncology Inc. | -13.92 Million USD | 88.557% |
| Precision Optics Corporation, Inc. | -2.72 Million USD | 41.527% |
| QuidelOrtho Corporation | 139.1 Million USD | 101.145% |
| Repligen Corporation | 54.57 Million USD | 102.919% |
| Sanara MedTech Inc. | -4.21 Million USD | 62.208% |
| STAAR Surgical Company | 28.09 Million USD | 105.67% |
| Sharps Technology, Inc. | -10.12 Million USD | 84.269% |
| Utah Medical Products, Inc. | 16.77 Million USD | 109.495% |
| DENTSPLY SIRONA Inc. | -85 Million USD | 98.126% |
| Jin Medical International Ltd. | 2.86 Million USD | 155.558% |